US2004191178A1PendingUtilityA1

Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine

58
Assignee: R T ALAMO VENTURES I INCPriority: Jul 5, 2001Filed: Feb 3, 2004Published: Sep 30, 2004
Est. expiryJul 5, 2021(expired)· nominal 20-yr term from priority
Inventors:Neal R. Cutler
A61K 9/006A61K 9/0043A61K 9/0007A61K 31/48
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is an improvement in the treatment of migraine headaches. By administering dihydroergotamine as a sublingual spray or aerosol, major limitations of past treatments are circumvented thereby allowing for higher efficacy and fewer side effects of treatment at lower doses.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method of treating migraine comprising: the application of a spray to the sublingual mucosa of a patient wherein said spray comprises dihydroergotamine and an ingredient selected from the group consisting of cyclodextrins, dextrans, sugar alcohols and mixtures thereof.  
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein said dextrans have average molecular weight between about 10,000 and about 100,000.  
     
     
         3 . A method of treating migraine comprising: the application of an aerosol to the sublingual mucosa of a patient wherein said aerosol comprises dihydroergotamine and an ingredient selected from the group consisting of cyclodextrins, dextrans, sugar alcohols and mixtures thereof.

Join the waitlist — get patent alerts

Track US2004191178A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.